CSA Medical, Inc. is pleased to announce the presentation of key findings related to truFreeze® Spray Cryotherapy at this year’s Digestive Disease Weekly (DDW) meeting in Washington DC.
BOSTON, May 31, 2018 /PRNewswire/ -- CSA Medical, Inc. is pleased to announce the presentation of key findings related to truFreeze® Spray Cryotherapy at this year’s Digestive Disease Weekly (DDW) meeting in Washington DC. The talks will highlight the efficacy of truFreeze Spray Cryotherapy for the treatment of Barrett’s esophagus and esophageal cancer. A full list of abstracts and presentations related to the truFreeze System are available on the CSA Medical website.
CSA Medical representatives will also be available for discussion and demonstration of the Rapid AV Catheter on the exhibit floor, in booth number 2734. The Rapid AV catheter, which is used with the truFreeze System, results in a 50% reduction in time to liquid nitrogen spray delivery to the treatment site, thus decreasing overall treatment time.
“This is an exciting time for the truFreeze franchise, with label expansion completed that includes ablation of Barrett’s Esophagus, high grade and/or low grade dysplasia. In addition, truFreeze remains the only ablation device whose label includes esophageal cancer,” says Ellen Sheets MD, CEO and President of CSA Medical. “We are pleased to be highlighting additional data related to the safety and efficacy of truFreeze for this full range of esophageal disease management.”
About CSA Medical
CSA Medical, Inc. develops and manufactures a proprietary interventional spray cryotherapy technology platform utilizing unique properties of liquid nitrogen spray delivered by a software driven device with specialty catheters that enable delivery of spray cryogen inside the body to flash freeze and destroy unwanted tissue allowing for a rejuvenative pattern of healing. CSA manufactures and distributes this technology in the USA as the truFreeze® system which is currently used to ablate benign (e.g. Barrett’s Esophagus with high grade dysplasia) and malignant lesions.
To learn more about our technology, please visit www.csamedical.com.
truFreeze is a registered trademark of CSA Medical, Inc.
For further information contact:
Teresa Prego, CSA Medical
+1-781-538-4793
tprego@csamedical.com
View original content with multimedia:http://www.prnewswire.com/news-releases/csa-medical-to-highlight-rapidav-catheter-and-presentations-of-trufreeze-clinical-studies-at-ddw-2018-300657424.html
SOURCE CSA Medical
